Release time：Nov 16, 2023
Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announces the appointment of Dr. Hai Wu as the President of R&D. He will be responsible for Mabwell’s R&D and global BD.
As one of the founders and CSO of Junshi Biosciences and TopAlliance Biosciences Inc., Dr. Wu was responsible for early discovery of dozens of antibody biotherapeutics, and made contributions to the MA approval of first China-made anti-PD-1 antibody. Prior to that, he served as R&D professional of novel biotherapeutics in Trellis Bioscience and Amgen. As senior scientist in Amgen, he was responsible for hybridoma mAb platform and participated in early-stage development of over 30 antibodies, bringing him rich experience in developing macromolecular drugs.
Dr. Wu obtained his Ph.D. in Genetics and Development from University of Texas Southwestern Medical Center and continued his postdoctoral training at Department of Pathology at Stanford University. He published high-level academic papers in internationally renowned academic journals.
Dr. Datao Liu, Co-founder, Chairman of the Board and CEO of Mabwell, said,“Warmly welcome Dr. Wu and we are more than excited to have him join Mabwell. Dr. Wu is not only a renowned scientist with strong academic background but also a powerful manager with extraordinary leadership and rich experience in drug research and development. We believe that Dr. Wu will bring added benefits to further strengthen our R&D capability and solidify our efforts in global.”
